Live Quote · NASDAQJANXHealthcare· Biotechnology

Janux Therapeutics, Inc.

$15.54 6.00%(+$0.88)
TickerSpark Score
48/100
Weak
60
Valuation
40
Profitability
10
Growth
80
Health
50
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JANX research report →

52-Week Range15% of range
Low
$12.12
Current
$15.54
High
$35.34
Company Overviewwww.januxrx.com

About the company

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors.

CEO
David Alan Campbell
IPO
2021
Employees
91
HQ
San Diego, CA, US

Price Chart

-35.41% · this period
$34.74$23.46$12.18Jul 02Dec 31Jul 02
Valuation
Market Cap
$947.70M
P/E
-8.45
P/S
43.85
P/B
1.03
EV/EBITDA
-8.16
Div Yield
0.00%
Profitability
Gross Margin
54.15%
Op Margin
-726.34%
Net Margin
-529.67%
ROE
-11.85%
ROIC
-16.15%
Growth & Income
Revenue
$10.00M · -5.55%
Net Income
$-113,625,000 · -64.69%
EPS
$-1.83 · -42.97%
Op Income
$-157,667,000
FCF YoY
-88.53%
Performance & Tape
52W High
$35.34
52W Low
$12.12
50D MA
$14.35
200D MA
$17.64
Beta
2.51
Avg Volume
1.11M

Get TickerSpark's AI analysis on JANX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 11, 26RA CAPITAL MANAGEMENT, L.P.other15,500
Jun 11, 26RA CAPITAL MANAGEMENT, L.P.other5,500
Jun 11, 26Simson Jakeother15,500
Jun 11, 26Simson Jakeother5,500
Jun 11, 26Kung Winstonother15,500
Jun 11, 26Kung Winstonother5,500
Jun 11, 26Hernday Natashaother15,500
Jun 11, 26Hernday Natashaother5,500
Jun 11, 26DOBMEIER ERICother15,500
Jun 11, 26DOBMEIER ERICother5,500
Coverage · JANX

Our JANX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on JANX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate JANX report →
Internal Compare

Similar companies

Peers in the same neighborhood.